The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a huge mover today! About 1.03M shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.74% since April 14, 2016 and is downtrending. It has underperformed by 20.43% the S&P500.
The move comes after 8 months positive chart setup for the $3.50B company. It was reported on Nov, 16 by Barchart.com. We have $49.59 PT which if reached, will make NASDAQ:ACAD worth $2.38 billion more.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage
Out of 7 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. ACADIA Pharmaceuticals has been the topic of 16 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Goldman Sachs initiated the stock with “Neutral” rating in Friday, November 11 report. Leerink Swann initiated the shares of ACAD in a report on Tuesday, October 4 with “Mkt Perform” rating. Needham maintained the stock with “Buy” rating in Friday, August 7 report. The firm has “Buy” rating given on Tuesday, November 8 by Bank of America. As per Thursday, August 27, the company rating was upgraded by Piper Jaffray. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Neutral” rating given on Friday, August 7 by Piper Jaffray. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Hold” rating given on Monday, August 10 by Vetr. As per Tuesday, May 3, the company rating was downgraded by Leerink Swann. The firm has “Buy” rating by JP Morgan given on Friday, September 4. The firm earned “Overweight” rating on Friday, August 7 by Piper Jaffray.
According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio dived, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Great West Life Assurance Company Can accumulated 0% or 9,295 shares. Utah Retirement has 16,400 shares for 0.01% of their US portfolio. Tekla Mngmt Ltd Liability Corp has 363,585 shares for 0.48% of their US portfolio. Huntington Bancshares has 0% invested in the company for 76 shares. Fortaleza Asset Mgmt has 3,836 shares for 0.1% of their US portfolio. The New York-based Senator Gp Ltd Partnership has invested 0.42% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). The Maryland-based Profund Advisors Ltd Llc has invested 0.08% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Frontier Capital Mngmt Limited Liability Co has 0.07% invested in the company for 271,231 shares. Fiera Corporation, a Quebec – Canada-based fund reported 193,473 shares. Massachusetts Serv Ma last reported 0% of its portfolio in the stock. North Star Investment Corp holds 880 shares or 0.01% of its portfolio. Schwab Charles Invest Management accumulated 0.01% or 198,523 shares. Eagle Asset Inc holds 955,027 shares or 0.21% of its portfolio. Jane Street Ltd Llc holds 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 40,310 shares. Teachers, a New York-based fund reported 107,238 shares.
Insider Transactions: Since July 11, 2016, the stock had 2 insider buys, and 2 insider sales for $42.17 million net activity. Shares for $560,033 were sold by Baity Glenn on Monday, July 11. BAKER BROS. ADVISORS LP had bought 1.30 million shares worth $43.00 million on Wednesday, August 10. HARRIGAN EDMUND bought $32,970 worth of stock or 1,000 shares.
ACAD Company Profile
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.